First Trust Nasdaq Pharmaceuticals ETF

Frequently Asked Questions About FTXH

What does FTXH invest in?

The First Trust Nasdaq Pharmaceuticals ETF (FTXH) operates as an exchange-traded fund. Its primary aim is to mirror the financial performance—both capital appreciation and income generation—of the Nasdaq US Smart Pharmaceuticals Index, prior to any fund-specific fees and expenses. To achieve this, the ETF endeavors to precisely replicate the constituents and their proportionate allocations within that index, striving for a performance correlation of at least 95%.

What is the expense ratio of FTXH?

First Trust Nasdaq Pharmaceuticals ETF (FTXH) charges an expense ratio of 0.60%. This is the annual fee deducted from fund assets to cover management and operations.

How big is FTXH?

First Trust Nasdaq Pharmaceuticals ETF (FTXH) manages $1.07B in total assets. AUM determines bid-ask liquidity and the fund's vulnerability to closure — funds below ~$50M are at higher risk of liquidation.

Is FTXH actively managed or an index fund?

FTXH's management style is described in the fund's prospectus. See the description on the Summary tab for the published strategy.

When was FTXH launched?

First Trust Nasdaq Pharmaceuticals ETF (FTXH) launched in September 2016 and is managed by First Trust.

How has FTXH performed?

FTXH's total return — price change plus reinvested distributions — is charted at the top of this page. Switch the price chart to Total Return and pick a 1-year, 3-year, 5-year, or 10-year window to read the compound annual growth rate (CAGR) over each horizon.